We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies.
- Authors
Ardizzone, Alessio; Basilotta, Rossella; Filippone, Alessia; Crupi, Lelio; Lanza, Marika; Lombardo, Sofia Paola; Colarossi, Cristina; Sciacca, Dorotea; Cuzzocrea, Salvatore; Esposito, Emanuela; Campolo, Michela
- Abstract
Primary brain tumors are a leading cause of death worldwide and are characterized by extraordinary heterogeneity and high invasiveness. Current drug and radiotherapy therapies combined with surgical approaches tend to increase the five-year survival of affected patients, however, the overall mortality rate remains high, thus constituting a clinical challenge for which the discovery of new therapeutic strategies is needed. In this field, novel immunotherapy approaches, aimed at overcoming the complex immunosuppressive microenvironment, could represent a new method of treatment for central nervous system (CNS) tumors. Chemokines especially are a well-defined group of proteins that were so named due to their chemotactic properties of binding their receptors. Chemokines regulate the recruitment and/or tissue retention of immune cells as well as the mobilization of tumor cells that have undergone epithelial–mesenchymal transition, promoting tumor growth. On this basis, this review focuses on the function and involvement of chemokines and their receptors in primary brain tumors, specifically examining chemokine-targeting immunotherapies as one of the most promising strategies in neuro-oncology.
- Subjects
BRAIN tumors; CHEMOKINE receptors; TUMOR growth; CENTRAL nervous system; EPITHELIAL-mesenchymal transition; IMMUNOTHERAPY
- Publication
Cells (2073-4409), 2023, Vol 12, Issue 6, p841
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells12060841